A Study of Baricitinib in Children With COVID-19 (COV-BARRIER-PEDS)

Recruitment & Eligibility

Status: Authorised-recruitment may be ongoing or finished

Sex: All

Target Recruitment: 24

Inclusion Criteria

- Male or female patients from 1 to <18 years of age at the time of enrollment
- Hospitalized with coronavirus (SARS-CoV-2) infection, confirmed by NAAT or immunodiagnostic tests, with a positive result in a sample collected no more than 14 days prior to treatment assignment
- Require supplmental oxygen and have chest imaging findings to confirm respiratory disease due to COVID-19 within 72 hours of study entry and enrollment
Are the trial subjects under 18? yes
Number of subjects for this age range: 24
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range 0
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range 0

Exclusion Criteria

- Are receiving biologic treatments (such as TNF inhibitors, interleukin inhibitors, T-cell or B-cell targeted therapies, interferons, or JAK inhibitors) for any indication at study entry; or are receiving other immunosuppressants such that, in the opinion of the investigator, participating in the study would put the participant at an unacceptable risk of immunosuppression. Note: A washout period is required prior to screening.
- Are receiving strong inhibitors of OAT3 (such as probenecid) that cannot be discontinued at study entry.
- Have diagnosis of current active tuberculosis (TB) or, if known, latent TB treated for less than 4 weeks with appropriate anti-tuberculosis therapy per local guidelines (by history only, no screening tests required)
- Suspected serious, active bacterial, fungal, viral, or other infection (besides COVID-19) that in the opinion of the investigator could constitute a risk when taking investigational product
- Have received any live vaccine within 4 weeks before screening, or intend to receive a live vaccine during the study. Note: use of nonlive (inactivated) vaccinations is allowed for all participants
- Require invasive mechanical ventilation, including extracorporeal membrane oxygenation (ECMO) at study entry
- Current diagnosis of active malignancy that, in the opinion of the investigator, could constitute a risk when taking investigational product
- Have any history of venous thromboembolism (VTE) (deep vein thrombosis [DVT] and/or pulmonary embolism [PE]) or are considered at high risk of VTE (DVT/PE) by the investigator
- Anticipated discharge from the hospital, or transfer to another hospital (or another unit), which is not a study site within 72 hours after study entry
- Have neutropenia (absolute neutrophil count < 1000 cells/microliters)
- Have lymphopenia (absolute lymphocyte count < 200 cells/microliters)
- Have alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >5 times AAULN
- Estimated glomerular filtration rate (eGFR) <40 milliliter/minute/1.73 meters squared

Study & Design

Study Type: Interventional clinical trial of medicinal product

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method

Secondary Outcome Measures

Name	Time	Method

Related Trials